hucMSCs Exosomes for the Treatment of Active Ulcerative Colitis

NCT06853522 | Not Yet Recruiting Early Phase 1

• 1 other identifier: 2025YS-004
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the safety and efficacy of hUC-MSCs-Exos in the treatment of ulcerative colitis.

Conditions

Ulcerative Colitis (UC)

Outcome Measures

Primary Outcomes (1)

• Mayo Score

  The complete Mayo Score consists of four assessments, each scored on a scale of 0 to 3: stool frequency, rectal bleeding, endoscopy, and the physician's global assessment (PGA) of disease activity. The endoscopy subscore of the complete Mayo Score is derived from the central reading of endoscopy results by a qualified central laboratory. Patient-reported stool frequency and rectal bleeding, as well as the PGA reported by the clinician, will be collected in an electronic diary.

  Baseline, 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.

Secondary Outcomes (25)

• Geboes Score

  Baseline, at 12 weeks after treatment.

• Inflammatory Bowel Disease Questionnaire (IBDQ)

  Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.

• The item of urgency to defecate

  Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.

• EQ-5D-5L

  Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.

• CRP (C - reactive protein)

  Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment.

Study Arms (2)

Exos Localized Treatment Group

EXPERIMENTAL

The corresponding exosome content of 60×10\^6 umbilical cord mesenchymal stem cells was given

Drug: exosomes derived from human umbilical cord mesenchymal stem cells

Placebo Localized Treatment Group

PLACEBO COMPARATOR

Equal amount of saline +5% albumin

Drug: saline +5% albumin

Interventions

exosomes derived from human umbilical cord mesenchymal stem cells DRUG

The corresponding exosome content of 60×10\^6 umbilical cord mesenchymal stem cells was given

Also known as: exosomes

Exos Localized Treatment Group

saline +5% albumin DRUG

Equal amount of saline +5% albumin was given

Also known as: placebo

Placebo Localized Treatment Group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects have had UC for at least 3 months (since symptom onset). The diagnosis should be confirmed by clinical and endoscopic evidence and confirmed by histopathological reports (note: if no previous reports are available, endoscopy and histopathology may be performed at the time of screening).
• Subjects had active UC, defined as four-component Mayo score of 6-12 (inclusive), endoscopy score ≥2, rectal bleeding score ≥1, and bowel frequency score ≥1.
• to 75 years old, weight ≥40 kg
• Meet at least one of the following a/b/c criteria: a. inadequate or non-response to one or more of the following treatments: i) oral prednisone ≥40mg/ day (or equivalent) or budesonide ≥9mg/ day or equivalent or beclomethasone ≥5mg/ day for at least 2 weeks. ii) At least 8 weeks of immunomodulators (AZA≥2 mg/kg/ day or 6-MP≥1.0mg/kg/ day \[or lower doses, but 6-thioguanine nucleotides with therapeutic concentrations recorded\]). iii) Oral administration of aminosalicylate (e.g. Mesalazine, salazine sulfopyridine, oxalazine, balsalazine) in accordance with the dosage and duration of the applicable local instructions. iv) The frontier therapy for UC has completed at least the induction dosing regimen, At doses greater than or equal to the approved instructions: anti-TNF anti-integrins (e.g., Vederizumab), JAK inhibitors (e.g., Tofaciib, Upatinib, or filgotinib), anti-IL-23 or anti-IL-12/23 drugs for the treatment of UC (e.g., ulinumab), S1PR modulators (e.g., ozamod) b. Corticosteroid dependence: failure to taper successfully to \<10mg/ day of prednisone or equivalent or \<6mg/ day of budesonide or \<5mg/ day of beclometasone within 3 months of starting treatment (i.e., disease onset), or relapse occurs within 3 months of stopping corticosteroids. c. Intolerance to 1 or 2 of the following treatments (e.g., inability to reach the therapeutic dose or duration of treatment due to dose-limiting adverse reactions) i) corticosteroids: Adverse reactions associated with dose-limiting therapy may include, but are not limited to, infections, hyperglycemia, osteoporosis, insomnia, or psychiatric disorders. ii) Immunomodulators: Adverse reactions associated with dose-restricted therapeutic administration may include, but are not limited to, infection, nausea/vomiting, fatigue, myelosuppression, or liver toxicity.
• Being treated with any of the following permitted drugs during the study period and meeting the drug stabilization requirements (if applicable): a. Oral corticosteroids must be stable for at least 2 weeks before randomization at an equivalent dose of ≤20 mg prednisone or ≤9mg budesonide or ≤5mg beclomethasone per day. b. A steady dose of oral aminosalicylate should be maintained for at least 2 weeks before randomization. c.AZA, 6-MP, or MTX(≤15 mg/ week) should be maintained at a stable dose for at least 4 weeks before randomization.
• Participate voluntarily and sign a written informed consent. -

You may not qualify if:

• Diagnosis of CD or undefined colitis (IBD- undefined) or other types of colitis or enteritis that may confuse assessment of effectiveness.
• The current diagnosis is explosive colitis and/or toxic megacolon.
• Had received fecal microbial transplantation within 4 weeks prior to randomization.
• Had been hospitalized for UC within 2 weeks prior to screening.
• There is clear evidence of past or current low or high grade colon dysplasia, including dysplasia detected during screening colonoscopy that has not been completely resectable.
• Have any active or severe infection that does not resolve after adequate treatment.
• Hepatitis B, hepatitis C virus infection, tuberculosis, HIV, uncontrollable diabetes, mental illness.
• Have undergone organ transplantation requiring sustained immunosuppressive therapy.
• A history of cancer within the past 5 years (except for completely treated non-melanoma skin cell carcinoma or carcinoma in situ of the cervix after complete surgical removal). Subjects who have had a diagnostic evaluation that suggests malignancy (e.g., chest or breast imaging) and who cannot reasonably rule out malignancy after additional clinical evaluation will be excluded from this study.
• A history of drug or alcohol abuse in the 6 months prior to screening (as reported by the subject).

Sponsors & Collaborators

• Shanghai East Hospital: lead

Study Sites (1)

Shanghai East Hospital

Shanghai, Shanghai Municipality, 200120, China

Location

MeSH Terms

Conditions

Colitis, Ulcerative

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases

Central Study Contacts

Lan Zhong

CONTACT

13162099450; lanzhong@tongji.edu.cn

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 13, 2025
• First Posted: March 3, 2025
• Study Start: May 30, 2025
• Primary Completion (Estimated): April 4, 2027
• Study Completion (Estimated): April 4, 2028
• Last Updated: April 27, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)